| Literature DB >> 31334228 |
Saeid Kargozar1, Maziar Montazerian2, Elisa Fiume3, Francesco Baino3,4.
Abstract
Improving and accelerating bone repair still are partially unmet needs in bone regenerative therapies. In this regard, strontium (Sr)-containing bioactive glasses (BGs) are highly-promising materials to tackle this challenge. The positive impacts of Sr on the osteogenesis makes it routinely used in the form of strontium ranelate (SR) in the clinical setting, especially for patients suffering from osteoporosis. Therefore, a large number of silicate-, borate-, and phosphate-based BGs doped with Sr and produced in different shapes have been developed and characterized, in order to be used in the most advanced therapeutic strategies designed for the management of bone defects and injuries. Although the influence of Sr incorporation in the glass is debated regarding the obtained physicochemical and mechanical properties, the biological improvements have been found to be substantial both in vitro and in vivo. In the present study, we provide a comprehensive overview of Sr-containing glasses along with the current state of their clinical use. For this purpose, different types of Sr-doped BG systems are described, including composites, coatings and porous scaffolds, and their applications are discussed in the light of existing experimental data along with the significant challenges ahead.Entities:
Keywords: bioactive glasses; cement; coating; osteogenesis; scaffold; strontium; tissue engineering
Year: 2019 PMID: 31334228 PMCID: PMC6625228 DOI: 10.3389/fbioe.2019.00161
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Figure 1Schematic representation of (A) melt-quenching and (B) sol-gel route for bioactive glass synthesis and final products.
Figure 229Si MAS-NMR (A) and FTIR (B) spectra related to glasses with various calcium-to-strontium substitutions. The results reveal no significant effects on structural properties and network connectivity (Fredholm et al., 2010). *represents spinning sideband.
Comparison among the Sr-doped glass systems discussed in the section Sr-containing BGs: an overview.
| Na2O/K2O/MgO/CaO/B2O3 SiO2/P2O5/SrO | M/B | Controlled release of borate and Sr2+ ions for new bone formation | -No crystallization upon doping | -Complete conversion to apatite | Li et al., |
| CaO/SrO/SiO2/MgO/P2O5 /CaF2 | M/S | Effect of Sr for Ca substitution on structural features, sintering behavior, and apatite-forming ability | - No changes in the glass structure | -Lower apatite-forming ability in SBF | Kargozar et al., |
| Na2O/SrO/SiO2/TiO2/CaO | M/S | Influence of Na+ and Sr2+ on solubility | - No changes in the glass structure | - Lower ion release rates | Ren et al., |
| B2O3/SrO/TiO2 B2O3/SrO/Na2O/TiO2 | M/B | Production of a borate glass system without the addition of other network formers; assessment of the physical, structural, thermal, and biological properties | -Higher Tg | - SrO content influences degradation rate and ion release | Yin et al., |
| CaO/SrO/SiO2/P2O5/Na2O | M/S | Influence of Sr for Ca substitution on physical properties | - No changes in the glass structure | _ | Baino et al., |
| CaO/ SrO-MgO/SiO2/Na2O K2O/P2O5 | M/S | Combination of the thermal behavior of Ca-rich silicate glasses with an improvement in biological results of MgO- and SrO-modified glasses | - Improved thermal stability | - Strong apatite-forming ability | Jones et al., |
| CaO/SrO/SiO2/MgO/Na2O K2O/ZnO/P2O5 | M/S | Influence of Sr/Ca substitution on the sintering behavior | - Lower Tg | _ | Baino, |
| SiO2/CaO/SrO | SG/S | Development of Sr-delivering glasses | - No alterations in the mesoporous texture | - Enhanced bioactivity | Wei et al., |
| SiO2/CaO/MgO/SrO | SG/S | Synthesis, characterization, and investigation of the apatite-forming ability in SBF | - Crystalline phases (calcium and strontium silicates) | - Good apatite-forming ability | Fiume et al., |
| CaO/SrO/P2O5/Na2/CaO/SrO | M/P | Glass fiber production | - Higher thermal stability | Reduced phosphate ions release | Baino et al., |
| P2O5/CaO/SrO/Na2O/MgO SrO | M/P | Investigation of phosphate glass formulation for controlled Sr release | - Lower Tg and Tm | - Higher chemical durability | Hench, |
| SiO2/P2O5/CaO/SrO | SG/S-P | Production and characterization of Sr-doped silico-phosphate glasses | - Higher Tp | - Higher biodegradation rate | Hesaraki et al., |
M, Melt-quenching route; SG, Sol-gel route; S, Silicate glasses; B, Borate glasses; P, Phosphate glasses; PW, Processing Window; Tg, Glass transition temperature; Tc, Crystallization onset temperature; Tp, Maximum rate of crystallization temperature; Tm, Melting temperature; SBF, Simulated body fluid. All the results are referred to the doped system, compared to the undoped one. If the effect of SrO replacement for another oxide is specifically investigated, the oxide couple (e.g., SrO/CaO) is indicated in the column “Glass system.”
Figure 3Diffusion pathways suggested for atoms of Na (green ball), Ca (blue ball), and Sr (pink ball). The other elements are depicted as Si (small yellow ball), P (small purple ball), O (small red ball) (Du and Xiang, 2012).
Compositions of PMMA cement and related Sr-BG/PMMA cements (Cui et al., 2017).
| Control (PMMA) | 0 | 2 | 0 | 1 | 2: 1 |
| 10Sr-BG/PMMA | 10 | 2 | 0.2 | 1 | 2.2: 1 |
| 20Sr-BG/PMMA | 20 | 2 | 0.4 | 1 | 2.4: 1 |
| 30Sr-BG/PMMA | 30 | 2 | 0.6 | 1 | 2.6: 1 |
Figure 4The microstructure of (A) PMMA bone cement, (B) 10Sr-BG/PMMA and (C) 30Sr-BG/PMMA composite cements (the black arrows indicate the Sr-doped BG particles). EDS mapping of the elements (D) Si and (E) Ca shows that Sr-BG particles are well-dispersed in the 30Sr-BG/PMMA composite cement [Adapted from Cui et al. (2017) with permission from The Royal Society].
Figure 5Micro-CT evaluation of bone regeneration in the rat tibia defects after implantation of PMMA and 30Sr-BG/PMMA composite cements. The 3D reconstructed sagittal images of the area surrounding the cement implants show new bone formation around the cement-host bone interface at (A) 8 and (B) 12 weeks (area outlined in red); (C) BV/TV (bone volume/total volume) in the defects implanted with 30SrBG/PMMA composite cement for different post-implantation times. Values are presented as mean ± s.d.; n = 3. *Significant difference between groups (p < 0.05) [Adapted from Cui et al. (2017) with permission from The Royal Society].
Figure 6SEM micrographs of electrospun composites made of (A) and (B) poly(caprolactone) (PCL); (C) and (D) PCL and particles of Sr-containing BG. The white arrows indicate that BG particles are embedded in the polymeric electrospun fibers [Adapted from Santocildes-Romero et al. (2016), after permission by Wiley and Sons].
Figure 7Backscattering SEM images of a Sr-doped 45S5 glass coating after 4 weeks of implantation in the rat femur (A). A detail of the different portions of the system is shown with arrows (B) [Adapted from Omar et al. (2015), after permission by Elsevier].
Physical, chemical, and biological properties of some Sr-doped or Sr-BGs containing materials described in section Bone cements.
| Sr-doped hydroxyapatite (HA) | Final setting time: 15–18 min | Compressive strength: ~41 MPa | Improving the osteoblast adhesion and mineralization | Cheung et al., |
| Sr-doped calcium phosphate-based cement (CPC) | Initial and final setting of 8–10 min and ~15 min, respectively | Compressive strength: ~12 MPa | Promoting cell proliferation and ALP activity of MG-63 cells cultured on the cement doped with Sr | Kuang et al., |
| Series of ionomer cements containing SiO2-ZnO–CaO–SrO based BGs | Working and setting time still have to be adjusted | Compressive strength: 39–75 MPa | Have to be evaluated after optimizing physical and mechanical properties | Boyd et al., |
| CPC containing 42SiO2-4P2O5-(39-x)CaO−15Na2O–xSrO (in mol%, x = 1.95, 3.90, 9.75, 19.5, 29.25, 39) | Final setting time: 20-40 min | Max. ompressive strength: 12.5 MPa | Forming | D'Onofrio et al., |
| Chitosan-based cement containing 5.5Na2O−7.34K2O−7.34MgO−20.18CaO−49.54B2O3−1.83P2O5−8.27SrO in mol% borate BGs | Initial setting time: 12 min | Max. compressive strength of 19 MPa | Enhancing the proliferation and osteogenic differentiation of hBMSCs | Zhang et al., |
| PMMA-based cement containing 6Na2O−8K2O−8MgO−16CaO−6SrO−27B2O3−27SiO2−2P2O5 (mol%) in mol% borosilicate BGs | Final setting time: 8–12 min | Max. compressive strength of 78–88 MPa | Promoting the adhesion, migration, proliferation, and collagen secretion of MC3T3-E1 cells | Cui et al., |
| PMMA-based cement (Spineple®) containing 40SiO2-30Na2O−20SrO−10 CaO in mol% BGs | Setting time: 16–18 min | Max. compressive strength of 75–100 MPa | – | O'Brien et al., |
| PMMA-based cement (Spineple®) containing SiO2-CaO–P2O5-SrO gel-derived BGs | Setting time: 16–20 min | Max. compressive strength: ~100 MPa | – | Goñi et al., |
Minimum requirement set by ISO 5833 for polymeric cements:
Max. peak temperature:: 908°C.
Setting times for operation in a surgical room 6–15 min.
Compressive strength > 70 MPa.
Flexural strength > 50 MPa.
Elasticity modulus > 1.8 GPa.
Figure 83D printing of Sr-doped MBGs: (A) photograph of 3D-printed scaffolds; SEM images of the MBG scaffolds doped with (B) 0 (control), (C) 5, (D) 10, and (E) 20 mol% of Sr. Images adapted from Zhang et al. (2014b).
Figure 9Borosilicate 13-93B2 glass foam doped with 6 mol% of Sr: (a) polyurethane foam used as a template; (b,c) foam-replicated scaffold; (d) apatite agglomerates formed on the surface of the scaffold after immersion in SBF for 5 days. Images adapted from Yin et al. (2018) with permission.
Figure 10The mechanisms proposed for the action of strontium ranelate (SrR) on the bone cells. SrR can stimulate bone formation through activating some well-known receptors such as the calcium-sensing receptor (CaSR) and increasing prostaglandin E2 (PE2) production by osteoblasts. In contrast, SrR can inhibit bone resorption via increasing osteoprotegerin and decreasing receptor activator of nuclear factor kappa B ligand (RANK) expression by osteoblasts. Adapted from Marie (2007) with permission.
Figure 11Micro-CT images from implantation of MBGs doped with 2.5 and 5% Sr in the critical femoral defect of ovariectomized rats at two, four, and 8 weeks post-surgery. The red circle and rectangle show the boundary of the defected sites. As shown, a little new bone is present in the defects at 2 weeks, while abundant new bone is observed at the other time points (four and 8 weeks) which depicted visible difference among the groups. Scale bar 2 mm. Adapted from Zhang et al. (2013) with permission by The Royal Society.